Market Overview

Physicians Likely To Support Portola's Betrixaban

Physicians Likely To Support Portola's Betrixaban

Morgan Stanley is bullish on Portola Pharmaceuticals Inc (NASDAQ: PTLA) following the FDA acceptance of betrixaban for priority review. With priority review, betrixaban will receive an accelerated assessment of six months with a PDUFA date of June 24, 2017.

Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE.

“We continue to believe physicians are likely to support betrixaban given the unmet need in VTE prophylaxis, however, the statistical review is likely to be the greatest area of pushback,” analyst Matthew Harrison wrote in a note.

Portola is yet to receive confirmation of an FDA advisory committee, but is expecting one to be convened. Harrison noted that the advisory committee will be key to shaping investor views of betrixaban approvability.

The stock’s next catalyst will come in the form of andexanet refilling in the second quarter 2017.

Harrison has an Overweight rating on Portola shares, with a price target of $29.

At last check, shares of Portola fell 6.46 percent to $23.44. Last Friday, the stock surged 34 percent on the FDA news to close at $25.06.

Latest Ratings for PTLA

May 2020Morgan StanleyMaintainsEqual-Weight
Apr 2020RBC CapitalInitiates Coverage OnOutperform
Jan 2020OppenheimerDowngradesOutperformPerform

View More Analyst Ratings for PTLA
View the Latest Analyst Ratings


Related Articles (PTLA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration FDA Best of Benzinga

Latest Ratings

PXDTruist SecuritiesMaintains175.0
GHCowen & Co.Maintains190.0
SITETruist SecuritiesMaintains186.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at